

May 12, 2021

Sumitomo Dainippon Pharma Co., Ltd.

Notice of Change of Trade Name and Partial Amendment to Articles of Incorporation

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that our Board of Directors resolved at a meeting held on May 12, 2021, to submit a proposal to the Ordinary General Meeting of Shareholders scheduled for June 24, 2021 to change its trade name and partially amend its Articles of Incorporation, as described below.

1. Change of Trade Name

(1) Reason for Change

In October 2005, Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceutical Co., Ltd. merged and its trade name is Sumitomo Dainippon Pharma Co., Ltd. In 2021, the company celebrates the 16th year since the merger. During that time, we have globalized our business, entered new areas such as oncology, regenerative medicine and cell therapy, and frontier business, and taken on numerous challenges such as large-scale acquisitions and partnerships, the company has undergone a major transformation since the merger.

In these circumstances, in order for the company to grow continuously, we have decided to change the name of the company from "Sumitomo Dainippon Pharma" to "Sumitomo Pharma" with the aim of maximizing the use of the simple and globally accepted "Sumitomo" brand and changing toward a new business stage.

(2) New Trade Name

Sumitomo Pharma Co., Ltd.

(3) New Brand Logo



(4) Scheduled Date for Change

April 1, 2022

*This change in the trade name is subject to approval of the partial amendment to the Articles of Incorporation at the Ordinary General Meeting of Shareholders to be held on June 24, 2021.

2. Partial Amendment to the Articles of Incorporation

(1) Reason for Change

Article 1 (Trade Name) of the current Articles of Incorporation will be amended in order to change the trade name as stated in "1. Change of Trade Name" above.

(2) Details of Change

The details of the change are as follows

(Underlined parts indicate changes)

Current Articles	Proposed Amendments
Chapter 1. General Rules (Trade Name) Article 1. The name of the Company shall be <u>Dainippon Sumitomo Seiyaku Kabushiki Kaisha</u> and, in English, its name shall be <u>Sumitomo Dainippon Pharma Co., Ltd.</u>	Chapter 1. General Rules (Trade Name) Article 1. The name of the Company shall be <u>Sumitomo Pharma Kabushiki Kaisha</u> and, in English, its name shall be <u>Sumitomo Pharma Co., Ltd.</u>

(3) Schedule

Date of General Meeting of Shareholders to amend the Articles of Incorporation

June 24, 2021 (scheduled)

Effective date of the amendment to the Articles of Incorporation

April 1, 2022 (scheduled)

3. Change in Trade Names of Subsidiaries

In conjunction with the change in the Company's trade name, the trade names of the Company's subsidiaries are scheduled to be changed as follows on April 1, 2022.

Current trade name	New trade name
Japan	
DSP GOKYO FOOD & CHEMICAL Co., LTD.	Sumitomo Pharma FOOD & CHEMICAL Co., LTD.
Address: 20F, HERBIS OSAKA, 5-25, Umeda 2-chome, Kita-ku, Osaka	
Representative: Nobuyuki Hara, President and CEO	
DS Pharma Animal Health Co., Ltd.	Sumitomo Pharma Animal Health Co., Ltd.
Address: 10F, METLIFE Honmachi Square, 5-7, Honmachi 2-chome, Chuo-ku, Osaka	
Representative: Kazuhiro Takada, President and CEO	
DS Pharma Promo Co., Ltd	Sumitomo Pharma Promo Co., Ltd.
33-94, Enoki-cho, Suita, Osaka	
Representative: Mitsuyuki Taniguchi, President and CEO	
DSP Associe Co., Ltd.	SMP Associe Co., Ltd.
Address: 6F, KT Building, 5-4, Hiranomachi 2-chome, Chuo-ku, Osaka	
Representative: Akiko Watanabe, President and CEO	
DSP Distribution Service Co., Ltd.	SMP Distribution Service Co., Ltd.

Address: 16-2, Yasakadai 3-chome, Suma-ku, Kobe, Hyogo	
Representative: Motoaki Matsushita, President and CEO	
DSP Business Partners Co., Ltd.	SMP Business Partners Co., Ltd.
Address: 6-8, Doshomachi 2-chome, Chuo-ku, Osaka	
Representative: Hajime Kinuta, President and CEO	
U.S.	
Sumitomo Dainippon Pharma America, Inc.	Sumitomo Pharma America Holdings, Inc.
Address: 84 Waterford Drive, Marlborough, MA 01752, U.S.	
Representative: Koji Ishida, Chair and CEO	
Sumitomo Dainippon Pharma Oncology, Inc.	Sumitomo Pharma Oncology, Inc.
Address: 640 Memorial Drive, Cambridge, MA 02139, U.S.	
Representative: Patricia S. Andrews, CEO	
China and Asia	
Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.	Sumitomo Pharma (Suzhou) Co., Ltd.
Address: No.115 QingQiu Street, SIP, Jiangsu Province, 215126 China	
Representative: Naoki Noguchi, Chairman and CEO	
Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd.	Sumitomo Pharma Asia Pacific Pte. Ltd.
Address: 3 Fraser Street, #07-28 DUO Tower, Singapore 189352	
Representative: Yoshitaka Koketsu, Managing Director	
Sumitomo Pharmaceuticals (Thailand) Co., Ltd.	Sumitomo Pharma (Thailand) Co., Ltd.
Address: Unit No. 1501, 15th Floor, Athenee Tower, 63 Wireless Road (Witthayu), Lumpini, Pathumwan, Bangkok 10330 Thailand	
Representative: Yukihide Mitsuyama, Managing Director	
Sumitomo Pharmaceuticals Taiwan Co., Ltd.	Sumitomo Pharma Taiwan Co., Ltd.
Address: 15F-2&-3, No.62, Nanjing W. Rd., Datong Dist., Taipei City 103, Taiwan (R.O.C.)	
Representative: Toyohiro Yoneda, Managing Director	

*There will be no change in the trade names of Sunovion Pharmaceuticals Inc., the companies of the Sumitovant Group, and S-RACMO Co., Ltd.

Contact

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: + 81-6-6203-1407 (Osaka); + 81-3-5159-3300 (Tokyo)